• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Pfizer Vaccine Causes a Frenzy of Buying

The vaccine news marks a major turning point and the issue now is to navigate this rotation.
By JAMES "REV SHARK" DEPORRE
Nov 09, 2020 | 10:33 AM EST
Stocks quotes in this article: PFE, ZM, PTON, M

News that Pfizer's (PFE)  covid vaccine was found to be over 90% effective in preventing Covid-19 has caused a frenzy of buying. There is a vicious rotation taking place as stocks that benefited from covid like Zoom Video (ZM) and Peloton (PTON) are being pounded, while money rotations into airlines, retail, and a variety of other stocks that have suffered recently.

There is quite of bit of selling into the stocks that are being chased and there are areas of major weakness like precious metals. Breadth is about 5 to 1 positive and the number of new 12-month highs has exploded to over 1000.

The FATMAAN names are mixed and are underperforming. This has been a 'safe haven' that outperformed during the covid crisis and now they are on the wrong side of the rotation.

To add to the chaos several major brokers are having technical problems. There are reports that Schwab, Merrill, and Fidelity are having major issues.

The vaccine news marks a major turning point and the issue now is to navigate this rotation.  Many of the 'stay at home' names are likely to see very strong business trends but others will see a sharp drop. Sorting out which ones have longer-term prospects is key.

Due to the broker issues, I have been unable to do much but I will be looking to play those names that benefit from reopening. One name on my radar is Macy's (M) which should be a leader in the retail space.  So far the big gap there is being sold but I will be looking for some support to form soon.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, James "Rev Shark" DePorre had no position in the securities mentioned.

TAGS: Drug Approvals | Investing | Markets | Stocks | Trading | Pharmaceuticals | Coronavirus

More from Investing

Is Inflation the Elephant in the Room -- Or Just a Mouse Scurrying By?

Maleeha Bengali
Apr 13, 2021 5:00 PM EDT

It's on every fund manager's mind, but how big a problem will it be and will it stick around?

This Kind of Inconsistency Can't Continue for Too Long

James "Rev Shark" DePorre
Apr 13, 2021 4:37 PM EDT

While the S&P 500 looks quite euphoric, many stocks are far from it.

Growth Doesn't Come From Issuing Press Releases

Timothy Collins
Apr 13, 2021 4:10 PM EDT

Smart investors can see through empty news statements about even the latest SPAC or NFT.

Planet Fitness Looks Out of Shape Right Now

Bruce Kamich
Apr 13, 2021 3:11 PM EDT

Our latest look at the PLNT charts.

American Airlines Still Has a Ticket to the Reopening

Mark Sebastian
Apr 13, 2021 2:58 PM EDT

Here's how to play AAL as it's off because of vaccine news.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:42 PM EDT PAUL PRICE

    Wednesday on Real Money Pro

    Make this stock a 'part' of your portfolio.
  • 04:44 PM EDT PAUL PRICE

    Pretty Incredible + Hard to Believe

  • 11:18 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 5 Pillars of Exceptional Trading
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login